ABB Technology Ventures made a profitable exit as it sold its share of cyber security company Industrial Defender to Lockheed Martin, which has fully acquired the business.

US-based cardiovascular drug developer Celladon has raised $50.6m in their initial public offering selling 6.325 million shares at $8 each.

Japanese chip design company Trigence Semiconductor has agreed to sell a minority stake to the state-run Innovation Network Corporation of Japan (INCJ).

Burstly, a smartphone app development company responsible for the beta-testing platform TestFlight, has been acquired by Apple.

Weibo has become the latest Chinese company to tap the US public markets, targeting $500 million from its initial public offering, and plans to leverage its partnership with minority shareholder Alibaba to maxmise advertising revenue.

Chemical company LG Chem is set to buy the US-based desalination membrane producer in a $200m deal that will provide exits for BASF and Total.

When Google Capital decided to invest $40m in US educational assessment company Renaissance Learning in February of this year, it perhaps did not consider a chunk of that investment would be realised about a month later. At the time of the investment the business was valued at $1bn and just a month later the business saw its value hit the $1.1bn mark when it was acquired by private equity firm Hellman & Friedman.

Aquinox Pharmaceuticals, a Canada clinical-stage pharmaceutical company discovering and developing novel oral drug candidates to treat inflammation and cancer, has listed on Nasdaq as part of an initial public offering. Corporate venturing investors include Johnson & Johnson and Pfizer. The net proceeds of the IPO were about $47m.

Allergy drug development firm Circassia floats on the London Stock Exchange in the biggest UK biotech initial public offering in years.